A single-center, open-label, phase 1 parallel-group single-dose, multiple-dose study evaluating the effect of mild to moderate hepatic impairment on the pharmacokinetics of Azilsartan and its major metabolite

Trial Profile

A single-center, open-label, phase 1 parallel-group single-dose, multiple-dose study evaluating the effect of mild to moderate hepatic impairment on the pharmacokinetics of Azilsartan and its major metabolite

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Azilsartan medoxomil (Primary)
  • Indications Hypertension
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 04 Aug 2017 New trial record
    • 27 Jul 2017 Results published in the Journal of Clinical Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top